A Homogeneous HTRF Assay for the Identification of Inhibitors of the TWEAK-Fn14 Protein Interaction

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1

Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139 · see citing works

Molecular properties that influence the oral bioavailability of drug candidates

Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420 · see citing works

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · see citing works

New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays

Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,963 · see citing works

The impact of aromatic ring count on compound developability – are too many aromatic rings a liability in drug design?

Ritchie, T. J., & Macdonald, S. J. F. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.07.014 · Cited by 913 · see citing works

TWEAK, a New Secreted Ligand in the Tumor Necrosis Factor Family That Weakly Induces Apoptosis

Chicheportiche, Y., Bourdon, P. R., Xu, H., Hsu, Y., Scott, H. S., Hession, C. A., Garcia, I., & Browning, J. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.51.32401 · Cited by 690 · see citing works

Small-Molecule Inhibition of TNF-α

He, M. M., Stroustrup, A., Oslob, J. D., Flanagan, W. M., Braisted, A. C., Whitty, A., Cancilla, M. T., Wang, J., Lugovskoy, A. A., Yoburn, J. C., et al. (2005) · Science · doi:10.1126/science.1116304 · Cited by 626 · see citing works

The TWEAK–Fn14 cytokine–receptor axis: discovery, biology and therapeutic targeting

Winkles, J. A. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2488 · Cited by 600 · see citing works

A Novel TNF Receptor Family Member Binds TWEAK and Is Implicated in Angiogenesis

Wiley, S. R., Cassiano, L., Lofton, T. E., Davis-Smith, T., Winkles, J. A., Lindner, V., Liu, H., Daniel, T. O., Smith, C. A., & Fanslow, W. C. (2001) · Immunity · doi:10.1016/s1074-7613(01)00232-1 · Cited by 378 · see citing works

TWEAK Induces NF-κB2 p100 Processing and Long Lasting NF-κB Activation

Saitoh, T., NAKAYAMA, M., Nakano, H., Yagita∥, H., Yamamoto, N., & Yamaoka, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304266200 · Cited by 303 · see citing works

TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor

Wiley, S. R., & Winkles, J. A. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00019-4 · Cited by 289 · see citing works

Targeting Protein–Protein Interactions for Therapeutic Intervention: A Challenge for the Future

Zinzalla, G., & Thurston, D. E. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.12 · Cited by 257 · see citing works

TWEAK Induces Angiogenesis and Proliferation of Endothelial Cells

Lynch, C. N., Wang, Y. C., Lund, J. K., Chen, Y., Leal, J. A., & Wiley, S. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.8455 · Cited by 243 · see citing works

TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1–TRAF2 complex to sensitize tumor cells to TNFα

Vince, J. E., Chau, D., Callus, B. A., Wong, W. W.-L., Hawkins, C. J., Schneider, P., McKinlay, M. A., Benetatos, C. A., Condon, S. M., Chunduru, S. K., et al. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200801010 · Cited by 236 · see citing works

A Previously Unrecognized Protein-Protein Interaction between TWEAK and CD163: Potential Biological Implications

Bover, L. C., Cardó‐Vila, M., Kuniyasu, A., Sun, J. D., Rangel, R., Takeya, M., Aggarwal, B. B., Arap, W., & Pasqualini, R. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.12.8183 · Cited by 216 · see citing works

The Mitogen-inducible Fn14 Gene Encodes a Type I Transmembrane Protein that Modulates Fibroblast Adhesion and Migration

Meighan‐Mantha, R. L., Hsu, D. K. W., Guo, Y. H., Brown, S. A. N., Feng, S.-L. Y., Peifley, K. A., Alberts, G. F., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.46.33166 · Cited by 200 · see citing works

The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation

Brown, S. A. N., Richards, C. M., Hanscom, H. N., Feng, S.-L. Y., & Winkles, J. A. (2003) · Biochemical Journal · doi:10.1042/bj20021730 · Cited by 181 · see citing works

TWEAK Is an Endothelial Cell Growth and Chemotactic Factor That Also Potentiates FGF-2 and VEGF-A Mitogenic Activity

Donohue, P. J., Richards, C. M., Brown, S. A. N., Hanscom, H. N., Buschman, J., Thangada, S., Hla, T., Williams, M. S., & Winkles, J. A. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000062883.93715.37 · Cited by 164 · see citing works

TWEAK Is a Novel Arthritogenic Mediator

Perper, S. J., Browning, B., Burkly, L. C., Weng, S., Gao, C. O., Giza, K., Su, L., Tarilonte, L., Crowell, T., Rajman, L. A., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2610 · Cited by 140 · see citing works

CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients

Speiser, D. E., Valmori, D., Rimoldi, D., Pittet, M. J., Líénard, D., Cerundolo, V., MacDonald, H. R., Cerottini, J., & Romero, P. J. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199906)29:06 · Cited by 119 · see citing works

Discovery of TNF Inhibitors from a DNA-Encoded Chemical Library based on Diels-Alder Cycloaddition

Buller, F., Zhang, Y., Scheuermann, J., Schäfer, J., Bühlmann, P., & Neri, D. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.09.011 · Cited by 109 · see citing works

TWEAK Induces Apoptosis through a Death-signaling Complex Comprising Receptor-interacting Protein 1 (RIP1), Fas-associated Death Domain (FADD), and Caspase-8

Ikner, A., & Ashkenazi, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.203745 · Cited by 94 · see citing works

The TNF superfamily in 2009: new pathways, new indications, and new drugs

Tansey, M. G., & Szymkowski, D. E. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.002 · Cited by 89 · see citing works

Soluble Tumor Necrosis Factor-Like Weak Inducer of Apoptosis Overexpression in HEK293 Cells Promotes Tumor Growth and Angiogenesis in Athymic Nude Mice

Ho, D. H., Vu, H., Brown, S. A. N., Donohue, P. J., Hanscom, H. N., & Winkles, J. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1879 · Cited by 85 · see citing works

Straightforward Recursive Partitioning Model for Discarding Insoluble Compounds in the Drug Discovery Process

Lamanna, C., Bellini, M., Padova, A., Westerberg, G., & Maccari, L. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701407x · Cited by 84 · see citing works

Full-length, Membrane-anchored TWEAK Can Function as a Juxtacrine Signaling Molecule and Activate the NF-κB Pathway

Brown, S. A. N., Ghosh, A., & Winkles, J. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.131979 · Cited by 74 · see citing works

Stability and equilibria of promiscuous aggregates in high protein milieus

Coan, K. E. D., & Shoichet, B. K. (2007) · Molecular BioSystems · doi:10.1039/b616314a · Cited by 72 · see citing works

Expression of TWEAK and Its Receptor Fn14 in the Multiple Sclerosis Brain: Implications for Inflammatory Tissue Injury

Serafini, B., Magliozzi, R., Rosicarelli, B., Reynolds, R., Zheng, T. S., & Aloisi, F. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31818dab90 · Cited by 71 · see citing works

TNF-like weak inducer of apoptosis inhibits proinflammatory TNF receptor-1 signaling

Wicovsky, A., Salzmann, S., Roos, C., Ehrenschwender, M., Rosenthal, T., Siegmund, D., Henkler, F., Gohlke, F., Kneitz, C., & Wajant, H. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.80 · Cited by 70 · see citing works

A Simple Assay for Detection of Small-Molecule Redox Activity

Lor, L. A., Schneck, J. L., McNulty, D. E., Diaz, E., Brandt, M. A., Thrall, S. H., & Schwartz, B. K. (2007) · SLAS DISCOVERY · doi:10.1177/1087057107304113 · Cited by 70 · see citing works

Small Molecule Inhibition of the TNF Family Cytokine CD40 Ligand through a Subunit Fracture Mechanism

Silvian, L. F., Friedman, J. E., Strauch, K., Cachero, T. G., Day, E. S., Qian, F., Cunningham, B. C., Fung, A. D., Sun, L., Su, L., et al. (2011) · ACS Chemical Biology · doi:10.1021/cb2000346 · Cited by 57 · see citing works

TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules

Brown, S. A. N., Hanscom, H. N., Vu, H., Brew, S. A., & Winkles, J. A. (2006) · Biochemical Journal · doi:10.1042/bj20051362 · Cited by 51 · see citing works

Inhibition of tumor necrosis factor-α (TNF-α)/ TNF-α receptor binding by structural analogues of suramin§§Abbreviations: TNF-α, tumor necrosis factor-α; and MC/EM, MonteCarlo/energy minimization.

Mancini, F., Toro, C. M., Mabilia, M., Giannangeli, M., Pinza, M., & Milanese, C. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00150-1 · Cited by 50 · see citing works

Tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 mediate cerebral ischemia-induced poly(ADP-ribose) polymerase-1 activation and neuronal death

Haile, W. B., Echeverry, R., Wu, F., Guzman, J., An, J., Wu, J., & Yepes, M. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.10.029 · Cited by 47 · see citing works

A Homogenous 384-Well High Throughput Screen for Novel Tumor Necrosis Factor Receptor: Ligand Interactions Using Time Resolved Energy Transfer

Moore, K. J., Turconi, S., Miles-Williams, A., Djaballah, H., Hurskainen, P., Harrop, J., Murray, K. J., & Pope, A. J. (1999) · SLAS DISCOVERY · doi:10.1177/108705719900400408 · Cited by 30 · see citing works

Solution structure of the cysteine‐rich domain in Fn14, a member of the tumor necrosis factor receptor superfamily

He, F., Dang, W., Saito, K., Watanabe, S., Kobayashi, N., Güntert, P., Kigawa, T., Tanaka, A., Muto, Y., & Yokoyama, S. (2009) · Protein Science · doi:10.1002/pro.49 · Cited by 27 · see citing works

A Homogeneous 384-Well High-Throughput Binding Assay for a TNF Receptor Using Alphascreen Technology

Wilson, J., Rossi, C. P., Carboni, S., Fremaux, C., Perrin, D., Soto, C. A., Kosco‐Vilbois, M. H., & Scheer, A. (2003) · SLAS DISCOVERY · doi:10.1177/1087057103257804 · Cited by 25 · see citing works

A homogeneous time-resolved fluorescence-based high-throughput screening system for discovery of inhibitors of IKKβ–NEMO interaction

Gotoh, Y., Nagata, H., Kase, H., Shimonishi, M., & Ido, M. (2010) · Analytical Biochemistry · doi:10.1016/j.ab.2010.05.028 · Cited by 15 · see citing works

Development of high-throughput radioligand binding assays for interleukin-1α (IL-1α) and tumor necrosis factor (TNF-α) in isolated membrane preparations

Maloff, B. L., & Delmendo, R. E. (1991) · Inflammation Research · doi:10.1007/bf01993258 · Cited by 7 · see citing works

Modulators of Protein–Protein Interactions

Milroy, L.-G., Grossmann, T. N., Hennig, S., Brunsveld, L., & Ottmann, C. (2014) · Chemical Reviews · doi:10.1021/cr400698c · Cited by 497 · see citing works

Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders

Xu, P., Shen, P., Yu, B., Xu, X. J., Ge, R., Cheng, X., Chen, Q., Bian, J., Li, Z., & Wang, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112155 · Cited by 79 · see citing works

TWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic

Cheng, E., Armstrong, C. L., Galisteo, R., & Winkles, J. A. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00473 · Cited by 54 · see citing works

Inhibition of Microglia Activation as a Phenotypic Assay in Early Drug Discovery

Figuera-Losada, M., Rojas, C. J., & Slusher, B. S. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113499406 · Cited by 50 · see citing works

Protein–Protein Interactions as Drug Targets

Skwarczynska, M., & Ottmann, C. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.138 · Cited by 50 · see citing works

Structural Basis and Targeting of the Interaction between Fibroblast Growth Factor-inducible 14 and Tumor Necrosis Factor-like Weak Inducer of Apoptosis

Dhruv, H., Loftus, J. C., Narang, P., Petit, J. L., Fameree, M., Burton, J., Tchegho, G., Chow, D. C., Yin, H., Al‐Abed, Y., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.493536 · Cited by 23 · see citing works

Screening for Small Molecule Disruptors of AKAP–PKA Interactions

Schächterle, C., Frank, C., Fernandes, J. M. P., & Klußmann, E. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2537-7_12 · Cited by 16 · see citing works

HSCARG Inhibits NADPH Oxidase Activity through Regulation of the Expression of p47phox

Xiao, W., Peng, Y., Liu, Y., Li, Z., Li, S., & Zheng, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059301 · Cited by 13 · see citing works

Non-stoichiometric inhibition in integrated lead finding – a literature review

Klumpp, M. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1128892 · Cited by 9 · see citing works

Experimental Methods Used for Identifying Small-Molecule Inhibitors of Protein-Protein Interaction

Zhou, M., Li, Q., Kong, W., & Wang, R. (2018) · Springer eBooks · doi:10.1007/978-981-13-0773-7_5 · Cited by 4 · see citing works

Disruptors of AKAP-Dependent Protein–Protein Interactions

Walker‐Gray, R., Pallien, T., Miller, D. C., Oder, A., Neuenschwander, M., von Kries, J. P., Diecke, S., & Klußmann, E. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2245-2_8 · Cited by 3 · see citing works

A yeast-based assay to screen protein-protein interaction modulators

Sudevan, A. (2021) · doi:10.70675/9ab04dcaz498fz43ebz8762z012f3f86154c

BindingDB Entry 50018729: Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders.

BindingDB (2024) · UC San Diego · doi:10.7270/q2cr5zm5

Structural Basis and Targeting of the Interaction between Fibroblast Growth Factor-inducible 14 and Tumor Necrosis Factor-like Weak Inducer of Apoptosis

Dhruv, H., Loftus, J. C., Narang, P., Petit, J. L., Fameree, M., Burton, J., Tchegho, G., Chow, D. C., Yin, H., Al‐Abed, Y., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.493536 · Cited by 23 · see citing works

The TWEAK ‐ Fn14 system as a potential drug target

Wajant, H. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12337 · Cited by 91 · see citing works

Inhibition of TWEAK Activity as a New Treatment for Inflammatory and Degenerative Diseases

Yepes, M., & Winkles, J. A. (2006) · Drug News & Perspectives · doi:10.1358/dnp.2006.19.10.1068005 · Cited by 20 · see citing works

The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation

Brown, S. A. N., Richards, C. M., Hanscom, H. N., Feng, S.-L. Y., & Winkles, J. A. (2003) · Biochemical Journal · doi:10.1042/bj20021730 · Cited by 181 · see citing works

TWEAK-Independent Fn14 Self-Association and NF-κB Activation Is Mediated by the C-Terminal Region of the Fn14 Cytoplasmic Domain

Brown, S. A. N., Cheng, E., Williams, M. S., & Winkles, J. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065248 · Cited by 48 · see citing works